Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Jeanette Kaae1, Berit Christina Carlsen1, Aska Drljevic-Nielsen2

  • 1Dermatologisk Afdeling, Sjællands Universitetshospital, Roskilde.

Ugeskrift for Laeger
|August 8, 2024
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026
Same author

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Journal of the National Cancer Institute·2026
Same author

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.

Acta dermato-venereologica·2026
Same author

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

European journal of cancer (Oxford, England : 1990)·2026
Same author

Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Ugeskrift for laeger·2026
Same journal

[Financial support scheme following a recognised occupational injury].

Ugeskrift for laeger·2026
Same journal

[Foreign body granulomas in the lungs after several years of parenteral nutrition].

Ugeskrift for laeger·2026
Same journal

[Vaginal aids for stress incontinence].

Ugeskrift for laeger·2026
Same journal

[Osteodystrophy in chronic liver disease].

Ugeskrift for laeger·2026
Same journal

[Tympanic membrane perforation].

Ugeskrift for laeger·2026
See all related articles

Immune checkpoint inhibitors (ICIs) improve cancer treatment but can cause skin issues. This review covers managing these common dermatological adverse events associated with ICIs.

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, significantly improving patient outcomes.
  • ICIs function by enhancing the host immune response against malignant cells.
  • A common challenge with ICIs is the occurrence of immune-related adverse events (irAEs) affecting various organs, notably the skin.

Purpose of the Study:

  • To provide a comprehensive overview of the evidence and clinical insights.
  • To detail the management strategies for dermatological adverse events stemming from ICI therapy.

Main Methods:

  • Literature review of existing evidence.
  • Synthesis of clinical experience.

Main Results:

Related Experiment Videos

  • Dermatological adverse events are among the most frequent irAEs associated with ICIs.
  • Effective management protocols are crucial for patient safety and treatment continuity.

Conclusions:

  • Managing skin toxicities is essential for patients undergoing ICI treatment.
  • This review offers guidance for clinicians dealing with ICI-induced dermatological conditions.